What is Amylin (IAPP)?

Co-secreted with insulin; the satiety and gastric-emptying partner. Structurally it is Islet amyloid polypeptide (37 aa).

How strong is the evidence for IAPP?

PeptideHormone grades IAPP at the "Established" evidence tier — its mechanism and core effects are settled across the peer-reviewed literature. It is catalogued as an endogenous signal the body produces itself, and the tier is an editorial judgment about the public literature that can change as the science does.

What is the half-life of IAPP?

The reported circulating half-life of IAPP is ~13 min (native).

AmylinIAPP

Co-secreted with insulin; the satiety and gastric-emptying partner.

EndogenousEstablishedCompare lineage

Released in the same breath as insulin and overlooked for a century — proof that even a well-mapped system still holds unread sentences.

Identity

Class: Islet amyloid polypeptide (37 aa)
Source: Pancreatic islet beta cells (with insulin)
Receptor: Amylin receptors (calcitonin receptor + RAMP complexes)

Key properties

Evidence floorClinicalREF1CLIN1

Molecular weight

~3,903.3 Da

REF

Half-life (native)

~13 min (native)

CLIN

Model dosing

Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.

Mechanism

Amylin is released alongside insulin and complements it: it slows gastric emptying, suppresses inappropriate glucagon secretion, and promotes satiety. Together with insulin it shapes the post-meal glucose excursion.

Reference notes

Amylin and insulin are co-packaged and co-secreted — a built-in partnership.
Amylin-pathway agonism is studied as an adjunct to incretin therapy for added satiety.
Native human amylin aggregates readily, which shaped the design of stabilized analogs.

Common questions

What is Amylin (IAPP)?: Co-secreted with insulin; the satiety and gastric-emptying partner. Structurally it is Islet amyloid polypeptide (37 aa).
How does IAPP work?: Amylin is released alongside insulin and complements it: it slows gastric emptying, suppresses inappropriate glucagon secretion, and promotes satiety. Together with insulin it shapes the post-meal glucose excursion.
How strong is the evidence for IAPP?: PeptideHormone grades IAPP at the "Established" evidence tier — its mechanism and core effects are settled across the peer-reviewed literature. It is catalogued as an endogenous signal the body produces itself, and the tier is an editorial judgment about the public literature that can change as the science does.
What is the half-life of IAPP?: The reported circulating half-life of IAPP is ~13 min (native).

Selected literature

Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.

1.Amylin: Pharmacology, Physiology, and Clinical Potential · Pharmacological reviews, 2015 · PMID 26071095
2.Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus · Nature reviews. Endocrinology, 2025 · PMID 40360789

External references

IAPP in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.